Processa Pharmaceuticals announced FDA clearance for the investigational new drug application to start a Phase 2 trial of VT-7208, a Bruton's tyrosine kinase inhibitor, targeting chronic spontaneous urticaria (CSU). The company is also expanding its immunology pipeline through a research collaboration with Generian Pharmaceuticals on a novel oral neonatal Fc receptor antagonist program. Sheila Gujrathi was appointed Executive Chair of the Board, and the company has secured funding expected to support operations into the second half of 2029. These developments mark significant progress in Processa's strategy to advance VT-7208 across multiple immune-mediated diseases and broaden its therapeutic portfolio.
Processa Pharmaceuticals' recent corporate and pipeline progress is presented here with Pluang's health sector market context. For readers following health stocks, as of Oct 29, 2026 18:11 WIB, 95 of 150 priced US health-sector stocks rose while 47 fell. Notable movers include Novartis AG (NVS) at USD 160.96 with a 3.13% gain and Pluang order activity of 58% Sell / 42% Buy, Sana Biotechnology Inc (SANA) at USD 2.71 up 3.04% with 96% Sell / 4% Buy, and Gilead Sciences, Inc. (GILD) at USD 163.65 rising 2.80% with 13% Sell / 87% Buy activity, typical hold times ranging from 25 to 114 days.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
